US 7,498,421 B2
Degradation fragments
Joseph Floyd Clark, Cincinnati, Ohio (US); Thomas Andrew Daniel Cadoux-Hudson, Oxford (United Kingdom); and Christopher Joseph Schofield, Oxford (United Kingdom)
Assigned to Medical Research Council, London (United Kingdom)
Filed on Jun. 30, 2006, as Appl. No. 11/479,024.
Application 11/479024 is a division of application No. 10/204950, granted, now 7,098,238, previously published as PCT/GB01/00830, filed on Feb. 26, 2001.
Prior Publication US 2007/0015816 A1, Jan. 18, 2007
Int. Cl. C07D 207/00 (2006.01); C07D 295/00 (2006.01); C07D 207/18 (2006.01); C12P 21/08 (2006.01); C07K 16/00 (2006.01); G01N 33/53 (2006.01)
U.S. Cl. 530—388.9  [548/400; 548/530; 548/565; 530/389.8; 530/391.3; 436/822] 2 Claims
 
1. An antibody that is specific for a compound of formula (I),

OG Complex Work Unit Drawing
wherein when X is ═CH(C═O)NH2, Y1 is hydrogen, and one of R1 and R2 is methyl and the other is —CH═CH2, or X is ═O, Y1 is hydrogen, R1 is —CH═CH2 and R2 is methyl.